3 completed, 2 recruiting, 1 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow Urothelial Carcinoma of the Bladder: new trials by email Literature Review of Urothelial Carcinoma of the Bladder trials Research Report on Urothelial Carcinoma of the Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) Perioperative Systemic Therapy Registry - Urothelial Carcinoma of the Bladder, Muscle Invasive Bladder Cancer (MIBC) | Recruiting | LMU Klinikum | 500 | 2026-05-17 | 2026-10-02 | |
| Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling - Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence | Recruiting | Zhiping Wang | 150 | 2026-04-01 | 2026-05-15 | |
| AN0025 and Pembrolizumab Combination in Advanced Solid Tumors AN0025, Pembrolizumab - Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous | Phase 1 | Unknown | Adlai Nortye Biopharma Co., Ltd. | 63 | 2020-08-20 | 2024-06-27 |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) Methotrexate, Vinblastine, Doxorubicin - Urothelial Carcinoma of the Bladder | Phase 2 | Completed | Fox Chase Cancer Center | 78 | 2016-02-24 | 2026-05-22 |
| Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts Blood Collection - Urothelial Carcinoma of the Bladder | Completed | Abramson Cancer Center at Penn Medicine | 87 | 2014-08-01 | 2020-12-10 | |
| Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer Proton therapy, IMRT - Urothelial Carcinoma of the Bladder | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 2 | 2012-01-01 | 2019-11-26 |
Carcinoma, Transitional Cell (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Disease Progression (1) · Neoplasms (1) · Pathologic Complete Response (1) · Recurrence (1) · Spinocerebellar Degenerations (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Carcinoma (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Brain Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1)
Blood Specimen Collection (1) · Cisplatin (1) · Doxorubicin (1) · E7046 (1) · Fluorouracil (1) · Methotrexate (1) · Mitomycin (1) · Proton Therapy (1) · Radiotherapy, Intensity-Modulated (1) · Transurethral Resection of Bladder (1) · Vinblastine (1) · pembrolizumab (1)
Abramson Cancer Center at Penn Medicine (2) · Adlai Nortye Biopharma Co., Ltd. (1) · Fox Chase Cancer Center (1) · LMU Klinikum (1) · Zhiping Wang (1)
United States (4) · China (1) · France (1) · Germany (1)
John Christodouleas, MD (2) · Robert Atkinson, Ph.D. (1) · Zhiping Wang (1)
2019 (1)